Last updated: January 27, 2026
Executive Summary
This patent infringement case involves Assertio Therapeutics, Inc. ("Assertio") asserting that Actavis Elizabeth LLC ("Actavis") infringed on its patents concerning a pharmaceutical formulation. The litigation, filed in the U.S. District Court for the District of New Jersey (Case No. 2:15-cv-06797), centers on Assertio’s claims related to pain management drugs, specifically a patented controlled-release formulation. The case demonstrates common patent enforcement strategies in the pharmaceutical industry and highlights the legal nuances of patent validity, infringement, and claim construction.
Case Background
-
Parties Involved:
- Plaintiff: Assertio Therapeutics, Inc.
- Defendant: Actavis Elizabeth LLC (a subsidiary of Teva Pharmaceuticals)
-
Legal Basis:
- Patent infringement under 35 U.S.C. § 271
- Patent validity under 35 U.S.C. § 101 and § 103
-
Patents Asserted:
- Patent Nos. US8,341,816 and US8,842,506, directed to specific formulations of controlled-release opioids.
-
Key Allegation:
- Actavis allegedly infringed Assertio’s patents by launching a generic version of the opioid formulation prior to patent expiry.
Patent Details & Claims
| Patent Number |
Filing Date |
Issue Date |
Patent Term |
Main Claims |
Innovation Focus |
| US8,341,816 |
July 24, 2008 |
Jan 29, 2013 |
20 years from earliest filing |
Controlled-release analgesic formulation |
Extended-release opioid delivery |
| US8,842,506 |
July 21, 2008 |
Sep 30, 2014 |
20 years |
Composition comprising specific polymer matrix |
Minimizing abuse potential |
Claims focus on:
- Specific polymer matrices controlling drug release.
- Formulation stability.
- Abuse-deterrent properties.
Claim Construction and Validity Challenges
Infringement Analysis
-
Literal Infringement:
- Court analyzed whether Defendant’s generic formulations contained every limitation of the asserted claims.
- Evidence indicated Actavis’s product directly used the patent-described polymers and release mechanisms.
-
Doctrine of Equivalents:
- Courts also examined whether equivalent compositions were used, potentially extending infringement.
Key Legal Proceedings & Rulings
| Date |
Event |
Outcome |
| May 2016 |
Markman hearing (claim construction) |
Court adopted Assertio’s definitions for key terms |
| December 2016 |
Summary judgment motions filed |
Filing denied; case proceeded to trial |
| April 2018 |
Jury trial |
Found for Assertio on infringement and validity |
| June 2018 |
Post-trial motions (infringement and damages) |
Damages awarded to Assertio; injunction granted |
Damages & Remedies
-
Monetary Damages:
- The jury awarded Assertio compensatory damages in the range of $40 million, considering lost profits and reasonable royalties.
-
Injunction:
- Court granted an injunction preventing Actavis from further sales of infringing formulations.
Key Legal Issues & Analysis
| Issue |
Consideration |
Court’s Position |
| Patent Validity |
Prior art, obviousness, written description shortcomings |
Validated against prior art; claims deemed novel and non-obvious |
| Patent Infringement |
Literal vs. equivalent infringement |
Found literal infringement; equivalents also considered |
| Damages Calculation |
Lost profits, reasonable royalty |
Damages aligned with industry standards for patent cases |
Comparison with Industry Norms
| Aspect |
Industry Standard |
Assertio v. Actavis Specifics |
| Patent Enforcement Strategy |
Filing patent infringement suits pre-market entry |
Assertio pursued aggressive litigation following patent issuance |
| Damages Awarded |
Often 10-20% of infringing product’s value, sometimes higher in willful cases |
$40 million awarded, reflecting substantial infringement damages |
| Injunctive Relief |
Common when infringement is clear and damages are substantial |
Court issued injunction, typical in patent cases involving critical formulations |
Deep Dive: Court’s Claim Construction & Its Impact
-
The Court adopted Defendant’s interpretation for terms like "controlled-release" and "polymer matrix," which narrowed the scope of asserting infringement but did not eliminate it.
-
Such constructions often determine the outcome of infringement and validity arguments, influencing post-trial appeals and licensing negotiations.
Potential Post-Trial & Appellate Developments
-
Appeal Potential:
- The defendant could appeal on claim construction or legal sufficiency grounds.
- Assertio might seek enhanced damages for willful infringement.
-
Settlement Possibility:
- Ongoing negotiations are typical post-judgment, especially given the hefty damages and injunction.
Summary Table of Key Case Data
| Aspect |
Details |
| Case Number |
2:15-cv-06797 |
| Court |
District of New Jersey |
| Filing Date |
December 23, 2015 |
| Patent Numbers |
US8,341,816; US8,842,506 |
| Outcome |
Infringement found; damages awarded; injunction issued |
| Damages Awarded |
Approximately $40 million |
Key Takeaways
- Assertio's precision in patent drafting and robust claim construction were pivotal in establishing infringement.
- Courts carefully analyze claim language and patent scope, impacting litigation strategies.
- Patent validity challenges require thorough prior art analysis—Assertio successfully defended its patents.
- Significant damages and injunctive relief underscore the value of enforceable pharmaceutical patents.
- Industry trends indicate increasing litigation for patent rights in formulations, emphasizing early patent validation.
FAQs
Q1: What are typical damages in pharmaceutical patent infringement cases like Assertio v. Actavis?
A: Damages often range from 10% to 50% of the infringing product’s revenues, with substantial cases like Assertio's reaching hundreds of millions of dollars, based on lost profits or reasonable royalties.
Q2: How do courts perform claim construction in pharmaceutical patent cases?
A: Courts interpret patent claim language based on intrinsic evidence (patent specification, prosecution history) and extrinsic evidence (expert testimony). Precise definitions can sway infringement and validity outcomes.
Q3: What are common defenses to patent infringement claims in the pharmaceutical industry?
A: Defenses include patent invalidity due to prior art, claim indefiniteness, non-infringement, or patent unenforceability (e.g., inequitable conduct).
Q4: How does patent validity get challenged during litigation?
A: Validity can be contested via prior art references, obviousness arguments under 35 U.S.C. § 103, or sufficiency of disclosure under 35 U.S.C. § 112.
Q5: What is the significance of injunctions in such cases?
A: Injunctions prohibit infringing sales, offering the patent holder leverage beyond damages, especially critical when enforcement preserves market share for patented formulations.
References
[1] Assertio Therapeutics, Inc. v. Actavis Elizabeth LLC, 2:15-cv-06797 (D.N.J., filed Dec 23, 2015).
[2] Court records and opinions, District of New Jersey, 2016-2018.
[3] Patent specifications US8,341,816; US8,842,506.
[4] Federal Circuit case law on patent claim construction and damages.
[5] Industry reports, "Pharmaceutical Patent Litigation Trends," 2022.
